The only randomized, placebo-controlled, Phase II trial using an HDAC inhibitor in pancreatic cancer tested the oral compound CI-994 in combination with gemcitabine and compared it to gemcitabine only [76]. This evidence concerns the gene HDAC9 and pancreatic neoplasm.